PROBLEM TO BE SOLVED: To provide anti-VEGF (vascular endothelial growth factor) antibody for blocking or preventing relapse tumor growth or relapse cancer cell growth, and for treating non-neoplastic conditions comprising chronic inflammation or atherosclerosis, and to provide its composition.SOLUTION: A VEGF antibody comprises HVR antibodies selected from six HVRs as follows: (i) an HVR-L1 comprising the amino acid sequence of X1X2R X3SL [X1 is G or A, X2 is V or I, and/or X3 is T or R], wherein the HVR-L1 comprises 1, 2 or 3 substitutions in any combination of the following positions； (ii) an HVR-L2 comprising the amino acid sequence of DASSLA； (iii) an HVR-L3 comprising the amino acid sequence of SYKSPL； (iv) an HVR-H1 comprising the amino acid sequence of SISGSWIF； (v) an HVR-H2 comprising the amino acid sequence of GAIWPFGGYTH； and (vi) an HVR-H3 comprising the amino acid sequence of RWGHSTSPWAMDY.【課題】再発腫瘍増殖又は再発癌細胞増殖を阻害又は予防、及び慢性炎症又はアテローム動脈硬化からなる非腫瘍性症状を治療のための抗血管内皮増殖因子（ＶＥＧＦ）抗体及びその組成物の提供。【解決手段】ＶＥＧＦ抗体は、（ｉ）Ｘ１Ｘ２ＲＸ３ＳＬのアミノ酸配列を含み、次の位置の任意の組合せで１、２又は３つの置換を含むＨＶＲ－Ｌ１［Ｘ１がＧ又はＡ、Ｘ２がＶ又はＩ、及び／又はＸ３がＴ又はＲ］；（ｉｉ）ＤＡＳＳＬＡのアミノ酸配列を含むＨＶＲ－Ｌ２；（ｉｉｉ）ＳＹＫＳＰＬのアミノ酸配列を含むＨＶＲ－Ｌ３；（ｉｖ）ＳＩＳＧＳＷＩＦのアミノ酸配列を含むＨＶＲ－Ｈ１；（ｖ）ＧＡＩＷＰＦＧＧＹＴＨのアミノ酸配列を含むＨＶＲ－Ｈ２；及び（ｖｉ）ＲＷＧＨＳＴＳＰＷＡＭＤＹのアミノ酸配列を含むＨＶＲ－Ｈ３の６つから選択されるＨＶＲ抗体を含む。【選択図】図１３
